APA

Amorim S., Stathis A., Gleeson M., Iyengar S., Magarotto V., Leleu X., Morschhauser F., Karlin L., Broussais F., Rezai K., Herait P., Kahatt C., Lokiec F., Salles G., Facon T., Palumbo A., Cunningham D., Zucca E. & Thieblemont C. (20171018). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. : The Lancet. Haematology.

Chicago

Amorim Sandy, Stathis Anastasios, Gleeson Mary, Iyengar Sunil, Magarotto Valeria, Leleu Xavier, Morschhauser Franck, Karlin Lionel, Broussais Florence, Rezai Keyvan, Herait Patrice, Kahatt Carmen, Lokiec François, Salles Gilles, Facon Thierry, Palumbo Antonio, Cunningham David, Zucca Emanuele and Thieblemont Catherine. 20171018. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. : The Lancet. Haematology.

Harvard

Amorim S., Stathis A., Gleeson M., Iyengar S., Magarotto V., Leleu X., Morschhauser F., Karlin L., Broussais F., Rezai K., Herait P., Kahatt C., Lokiec F., Salles G., Facon T., Palumbo A., Cunningham D., Zucca E. and Thieblemont C. (20171018). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. : The Lancet. Haematology.

MLA

Amorim Sandy, Stathis Anastasios, Gleeson Mary, Iyengar Sunil, Magarotto Valeria, Leleu Xavier, Morschhauser Franck, Karlin Lionel, Broussais Florence, Rezai Keyvan, Herait Patrice, Kahatt Carmen, Lokiec François, Salles Gilles, Facon Thierry, Palumbo Antonio, Cunningham David, Zucca Emanuele and Thieblemont Catherine. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. : The Lancet. Haematology. 20171018.